Greenwich LifeSciences (GLSI) Cash from Financing Activities (2020 - 2025)

Greenwich LifeSciences' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $5.5 million for Q4 2025.

• Quarterly Cash from Financing Activities rose 4452.04% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.0 million (up 174.64% YoY) and the FY2025 annual result came in at $12.0 million, up 174.64% from the prior year.
• Cash from Financing Activities was $5.5 million for Q4 2025 at Greenwich LifeSciences, up from $3.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $5.5 million in Q4 2025 and bottomed at -$5.5 million in Q1 2022.
• A 4-year average of $972318.2 and a median of $872010.0 in 2021 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 342.59% — and 2025, when it jumped 4452.04%.
• Greenwich LifeSciences' Cash from Financing Activities stood at $562596.0 in 2021, then sank by 459.5% to -$2.0 million in 2022, then soared by 106.02% to $121829.0 in 2024, then soared by 4452.04% to $5.5 million in 2025.
• Business Quant data shows GLSI's Cash from Financing Activities at $5.5 million in Q4 2025, $3.4 million in Q3 2025, and $2.6 million in Q2 2025.